Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H2 2016', provides in depth analysis on Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted pipeline therapeutics. 

The report provides comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) 
- The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) Overview 9
Therapeutics Development 10
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Products under Development by Stage of Development 10
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Products under Development by Therapy Area 11
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Products under Development by Indication 12
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Products under Development by Companies 17
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Products under Development by Universities/Institutes 22
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment 24
Assessment by Monotherapy/Combination Products 24
Assessment by Mechanism of Action 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development 29
Aptose Biosciences Inc. 29
Arvinas, Inc. 30
C4 Therapeutics, Inc. 31
Constellation Pharmaceuticals, Inc. 32
ConverGene, LLC 33
Daiichi Sankyo Company, Limited 34
Dybly AG 35
F. Hoffmann-La Roche Ltd. 36
Incyte Corporation 37
Kainos Medicine, Inc. 38
Merck & Co., Inc. 39
Resverlogix Corp. 40
Trillium Therapeutics Inc. 41
Zenith Epigenetics Corp 42
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles 43
apabetalone - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ARV-763 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
ARV-771 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ARV-825 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
birabresib - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
CK-103 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
CPI-0610 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
CVG-101 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
DYB-186 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
INCB-54329 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
KM-601 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
MA-2014 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
MS-417 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
NEO-2734 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
PLX-51107 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
RG-6146 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
S-10 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
SF-2535 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecules to Inhibit BRD4 for Oncology - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecules to Target BRD4 and VHL for Lung Cancer - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small Molecules to Target BRD4 and VHL for Ovarian Cancer - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
SRX-2523 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
TTI-281 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
ZEN-3365 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
ZEN-3694 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Projects 79
Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Featured News & Press Releases 80
Aug 04, 2016: The Life Sciences Report Examines Resverlogix New Trial 80
Jul 21, 2016: Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs 80
Jun 15, 2016: Zenith Announces Dosing of First Patient in Phase 1 Clinical Trial and Corporate Update Webcast Details 81
Jun 02, 2016: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016 81
May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 82
Jan 25, 2016: Resverlogix Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal 83
Nov 11, 2015: Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE 83
Nov 09, 2015: Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference 83
Oct 26, 2015: Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone 84
Sep 29, 2015: Resverlogix Provides Research and Development Update in New York City 84
Sep 24, 2015: Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases 85
Aug 31, 2015: Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor 85
Aug 04, 2015: International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone" 86
Jun 22, 2015: Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority 87
Jun 08, 2015: Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List of Tables

Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Comparative Analysis by Unknown Stage Development, H2 2016 16
Number of Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Development by Companies, H2 2016 (Contd..2) 20
Products under Development by Companies, H2 2016 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Products under Investigation by Universities/Institutes, H2 2016 23
Assessment by Monotherapy/Combination Products, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 28
Pipeline by Aptose Biosciences Inc., H2 2016 29
Pipeline by Arvinas, Inc., H2 2016 30
Pipeline by C4 Therapeutics, Inc., H2 2016 31
Pipeline by Constellation Pharmaceuticals, Inc., H2 2016 32
Pipeline by ConverGene, LLC, H2 2016 33
Pipeline by Daiichi Sankyo Company, Limited, H2 2016 34
Pipeline by Dybly AG, H2 2016 35
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 36
Pipeline by Incyte Corporation, H2 2016 37
Pipeline by Kainos Medicine, Inc., H2 2016 38
Pipeline by Merck & Co., Inc., H2 2016 39
Pipeline by Resverlogix Corp., H2 2016 40
Pipeline by Trillium Therapeutics Inc., H2 2016 41
Pipeline by Zenith Epigenetics Corp, H2 2016 42
Dormant Projects, H2 2016 79